Eculizumab for Atypical Hemolytic–Uremic Syndrome | Zendy

Yilong  Wang | Zendy; Beijing  Tiantan | Zendy; S. Claiborne Johnston | Zendy; Yongjun  Wang | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Eculizumab for Atypical Hemolytic–Uremic Syndrome

Author(s) -

Yilong Wang,

Beijing Tiantan,

S. Claiborne Johnston,

Yongjun Wang

Publication year - 2009

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmx090009

Subject(s) - eculizumab , medicine , atypical hemolytic uremic syndrome , intensive care medicine , pediatrics , immunology , complement system , antibody

[CI], 0.57 to 0.83) for the first 21 days, 1.00 (95% CI, 0.57 to 1.76) for 22 to 60 days, and 0.38 (95% CI, 0.18 to 0.82) for 61 to 90 days. We also await results of trials such as POINT and TARDIS for confirmation of these results in non-Chinese populations. We agree with Jeong that there may be important differences according to the patients’ eth nicity and environment that limit the generalizability of our results, and we await the results of future clinical trials.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research